300255.SZ
常山药业
SZSE · Healthcare · C 制造业 · CN
CNY 23.38
−4.69%Year over year
Reported trailing growth
- Revenue
- -12.3%
- EBITDA
- —
- EBIT
- -81.9%
- EPS
- —
- Free cash flow
- +13.8%
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -27.9%
- EBITDA
- -55.5%
- EBIT
- -37.9%
- Net income
- -43.5%
- EPS
- -44.4%
- Free cash flow
- +63.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026